JW신약

067290KOSDAQ

74.3 / 100

Reference Date: 2026-09-08

Financial Score23.0 / 40

News Sentiment21.3 / 25

Momentum20.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Surged 64.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

JW Shinapharm primarily engages in the manufacturing and sales of pharmaceuticals, building a systematic sales network through joint marketing with JW Chungwa Pharmaceutical. Its subsidiary, JW Crigen, specializes in cell therapy products. In 2024, the company achieved consolidated sales of 93 billion won and an operating profit of 10 billion won. Key products include antifungal medications, dermatological treatments, and internal medicine drugs.

Number of Employees

173people

Average Salary

69.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

14.61Industry Average 15.005.0Point

In line with industry avg

PBR

4.93Industry Average 1.200.0Point

4.1x industry avg (risky)

ROE

46.53Industry Average 8.007.0Point

5.8x industry avg (excellent)

Debt Ratio

5.17Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲25.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -11.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
JW신약, 탈모 건보 확대 기대감에 이틀째 강세
JW신약의 탈모 치료제 건강보험 확대 기대감으로 이틀 연속 강세를 보임.

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 3,580Won52-week high 3,58052-week low 1,294

1-month return6.0Point

1m +64.22% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기보고서 (2026.06)2026-08-14
Neutral영업(잠정)실적(공정공시)2026-08-12